Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Salisch, Nadine C ^a   Vujadinovic, Marija ^a   Van Der Helm, Esmeralda ^a   Spek, Dirk ^a   Vorthoren, Lars ^a,b   Serroyen, Jan ^a   Kuipers, Harmjan ^a   Schuitemaker, Hanneke ^a   Zahn, Roland ^a   Custers, Jerome ^a   Vellinga, Jort ^a  

^a Janssen Research and Development   (Netherlands)

^b PROQR THERAPEUTICS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; CAPSID PROTEIN IX; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; GLYCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; UNCLASSIFIED DRUG; MALARIA VACCINE;

ADENOVIRIDAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL SURFACE DISPLAY; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; HUMAN ADENOVIRUS 35; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; TRANSGENE; ANIMAL; BAGG ALBINO MOUSE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; MALARIA FALCIPARUM; METABOLISM;

ADENOVIRUSES, HUMAN; ANIMALS; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENETIC VECTORS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; PLASMODIUM FALCIPARUM;

EID: 85016646491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174728     Document Type: Article

References (46)

1. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22):2083-92. PubMed Central PMCID: PMC4030634. https://doi.org/10.1056/NEJMoa1310566 PMID: 24099601
2. Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. Journal of translational medicine. 2013; 11:62. PubMed Central PMCID: PMC3599587. https://doi.org/10.1186/1479-5876-11-62 PMID: 23497415
3. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Science translational medicine. 2013; 5(205):205ra134. https://doi.org/10.1126/scitranslmed.3006843 PMID: 24089406
4. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. Journal of virology. 2004; 78(6):2666-73. PubMed Central PMCID: PMC353774. https://doi.org/10.1128/JVI. 78.6.2666-2673.2004 PMID: 14990686
5. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-93. PubMed Central PMCID: PMC2721012. https://doi.org/10.1016/S0140-6736(08)61591-3 PMID: 19012954
6. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. Journal of immunology. 2004; 172(10):6290-7.
7. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 29(32):5203-9. https://doi.org/10.1016/j.vaccine.2011.05.025 PMID: 21619905
8. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature medicine. 2014; 20(10):1126-9. https://doi.org/10.1038/nm.3702 PMID: 25194571
9. Rodriguez A, Mintardjo R, Tax D, Gillissen G, Custers J, Pau MG, et al. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine. 2009; 27 (44):6226-33. https://doi.org/10.1016/j.vaccine.2009.07.106 PMID: 19686691
10. Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clinical and vaccine immunology: CVI. 2011; 17(11):1687-94.
11. Ouedraogo A, Tiono AB, Kargougou D, Yaro JB, Ouedraogo E, Kabore Y, et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PloS one. 2013; 8(11):e78679. PubMed Central PMCID: PMC3823848. https://doi.org/10.1371/journal.pone.0078679 PMID: 24244339
12. Soler E, Houdebine LM. Preparation of recombinant vaccines. Biotechnol Annu Rev. 2007; 13:65-94. https://doi.org/10.1016/S1387-2656(07)13004-0 PMID: 17875474
13. Rts SCTP Agnandji ST, Lell B Fernandes JF, Abossolo BP Methogo BG, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367(24):2284-95. https://doi.org/10.1056/NEJMoa1208394 PMID: 23136909
14. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. The Journal of infectious diseases. 2009; 200(3):337-46. https://doi.org/10.1086/600120 PMID: 19569965
15. Olotu AI, Fegan G, Bejon P. Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults. The Journal of infectious diseases. 2010; 201(6):970-1. https://doi.org/10.1086/651025 PMID: 20170369
16. Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and immunity. 2007; 75(5):2283-90. https://doi.org/10.1128/IAI.01879-06 PMID: 17307942
17. Matthews QL. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm. 2011; 8(1):3-11. PubMed Central PMCID: PMC3034826. https://doi.org/10.1021/mp100214b PMID: 21047139
18. Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. Journal of virology. 2006; 80(11):5523-30. PubMed Central PMCID: PMC1472137. https://doi.org/10.1128/JVI. 02667-05 PMID: 16699033
19. Furcinitti PS, van Oostrum J, Burnett RM. Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography. The EMBO journal. 1989; 8(12):3563-70. PubMed Central PMCID: PMC402035. PMID: 2583109
20. van Oostrum J, Burnett RM. Molecular composition of the adenovirus type 2 virion. Journal of virology. 1985; 56(2):439-48. PubMed Central PMCID: PMC252598. PMID: 4057357
21. Meulenbroek RA, Sargent KL, Lunde J, Jasmin BJ, Parks RJ. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIXGFP. Molecular therapy: the journal of the American Society of Gene Therapy. 2004; 9(4):617-24.
22. Matthews QL, Sibley DA, Wu H, Li J, Stoff-Khalili MA, Waehler R, et al. Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Molecular imaging. 2006; 5(4):510-9. PubMed Central PMCID: PMC1781529. PMID: 17150163
23. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. Journal of virology. 2002; 76(14):6893-9. PubMed Central PMCID: PMC136342. https://doi.org/10.1128/JVI.76.14.6893-6899.2002 PMID: 12072490
24. Vellinga J, Rabelink MJ, Cramer SJ, van den Wollenberg DJ, Van der Meulen H, Leppard KN, et al. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. Journal of virology. 2004; 78(7):3470-9. PubMed Central PMCID: PMC371045. https://doi.org/10.1128/JVI.78.7.3470-3479.2004 PMID: 15016870
25. Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S, Uberla K, et al. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. Journal of virology. 84(4):1967-76. https://doi.org/10.1128/JVI.01840-09 PMID: 20007267
26. Boyer JL, Sofer-Podesta C, Ang J, Hackett NR, Chiuchiolo MJ, Senina S, et al. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Human gene therapy. 2010; 21(7):891-901. PubMed Central PMCID: PMC2938358. https://doi.org/10.1089/hum.2009.148 PMID: 20180652
27. Ophorst OJ, Radosevic K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine. 2007; 25(35):6501-10.https://doi.org/10.1016/j.vaccine.2007.06.019 PMID: 17646036
28. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replicationdeficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. Journal of virology. 2003; 77(15):8263-71. PubMed Central PMCID: PMC165227. https://doi.org/10.1128/JVI.77.15.8263-8271.2003 PMID: 12857895
29. Maizel JV Jr., White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968; 36(1):115-25. PMID: 5669982
30. Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, et al. Novel replicationincompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. The Journal of general virology. 2006; 87(Pt 8):2135-43. https://doi.org/10.1099/vir.0.81956-0 PMID: 16847108
31. Nakai M, Komiya K, Murata M, Kimura T, Kanaoka M, Kanegae Y, et al. Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. Human gene therapy. 2007; 18(10):925-36. https://doi.org/10.1089/hum.2007.085 PMID: 17907966
32. Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Segard H, et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. Journal of virology. 2002; 76(1):127-35. https://doi.org/10.1128/JVI.76.1.127-135.2002 PMID: 11739678
33. Aley SB, Bates MD, Tam JP, Hollingdale MR. Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro. J Exp Med. 1986; 164(6):1915-22. PubMed Central PMCID: PMC2188491. PMID: 3023519
34. Plassmeyer ML, Reiter K, Shimp RL Jr., Kotova S, Smith PD, Hurt DE, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. The Journal of biological chemistry. 2009; 284(39):26951-63. https://doi.org/10.1074/jbc.M109.013706 PMID: 19633296
35. Carrasco YR, Batista FD. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity. 2007; 27(1):160-71. https://doi.org/10.1016/j.immuni.2007.06.007 PMID: 17658276
36. Vogelstein B, Dintzis RZ, Dintzis HM. Specific cellular stimulation in the primary immune response: a quantized model. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79(2):395-9. PMID: 6952192
37. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Human gene therapy. 2002; 13(1):129-41. https://doi.org/10.1089/10430340152712683 PMID: 11779417
38. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(50):E3503-12. PubMed Central PMCID: PMC3528489. https://doi.org/10.1073/pnas. 1208972109 PMID: 23151505
39. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003; 4(10):1009-15. https://doi.org/10.1038/ni978 PMID: 14502286
40. Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G, et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology. 2011; 8:75. PubMed Central PMCID: PMC3193818. https://doi.org/10.1186/1742-4690-8-75 PMID: 21943056
41. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. Journal of virology. 86(18):9590-8. https://doi.org/10.1128/JVI.00740-12 PMID: 22787208
42. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Molecular therapy: the journal of the American Society of Gene Therapy. 2004; 10(4):616-29.
43. Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. Journal of virology. 2004; 78(20):11434-8. https://doi.org/10.1128/JVI. 78.20.11434-11438.2004 PMID: 15452269
44. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002; 20(7-8):1039-45. PMID: 11803063
45. Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. Journal of virology. 2004; 78 (14):7490-7. https://doi.org/10.1128/JVI.78.14.7490-7497.2004 PMID: 15220422
46. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415 (6869):331-5. https://doi.org/10.1038/415331a PMID: 11797011